CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $76.29 Average Target Price from Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned an average recommendation of “Hold” from the sixteen research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $76.29.

A number of brokerages have recently issued reports on CRSP. Royal Bank of Canada increased their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Wolfe Research started coverage on shares of CRISPR Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Citigroup boosted their price target on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Finally, Wells Fargo & Company lifted their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd.

CRISPR Therapeutics Stock Down 1.3 %

NASDAQ CRSP opened at $55.65 on Monday. The stock has a market capitalization of $4.72 billion, a P/E ratio of -28.39 and a beta of 1.76. CRISPR Therapeutics has a 52-week low of $37.55 and a 52-week high of $91.10. The firm has a 50-day moving average price of $71.75 and a 200 day moving average price of $63.80.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. During the same period last year, the company posted ($1.41) earnings per share. The business’s quarterly revenue was up 3253.3% on a year-over-year basis. On average, equities research analysts expect that CRISPR Therapeutics will post -6.24 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the sale, the chief financial officer now owns 6,476 shares of the company’s stock, valued at $470,740.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,992 shares of company stock valued at $9,157,835. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC grew its holdings in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares during the period. Tradewinds Capital Management LLC raised its position in shares of CRISPR Therapeutics by 545.5% in the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares during the period. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $32,000. Headlands Technologies LLC purchased a new stake in CRISPR Therapeutics during the third quarter valued at about $34,000. Finally, Bourgeon Capital Management LLC increased its stake in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.